Last reviewed · How we verify
Prolyl Endopeptidase
Prolyl Endopeptidase is a Serine protease / Enzyme Small molecule drug developed by Dr. C. Bonorino Udaondo Gastroenterology Hospital. It is currently FDA-approved for Gastrointestinal disorders (specific indication unclear from available information). Also known as: GliadinX.
Prolyl endopeptidase is an enzyme that cleaves peptide bonds after proline residues, potentially modulating neuropeptide and protein processing in the gastrointestinal and nervous systems.
Prolyl Endopeptidase is an enzyme being studied for its potential to aid in the digestion of gluten in individuals with Non-coeliac Gluten Sensitivity, Celiac Disease, Irritable Bowel Syndrome, and Abdominal Bloating. It is being investigated as part of the AN-PEP intervention in clinical trials.
At a glance
| Generic name | Prolyl Endopeptidase |
|---|---|
| Also known as | GliadinX |
| Sponsor | Dr. C. Bonorino Udaondo Gastroenterology Hospital |
| Drug class | Serine protease / Enzyme |
| Target | Prolyl endopeptidase (PEP) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Prolyl endopeptidase (PEP) is a serine protease that specifically hydrolyzes peptide bonds on the C-terminal side of proline residues. This enzymatic activity may influence the metabolism of bioactive peptides involved in gastrointestinal function, potentially affecting motility, secretion, and nutrient absorption. The enzyme's role in peptide processing suggests therapeutic applications in gastrointestinal disorders.
Approved indications
- Gastrointestinal disorders (specific indication unclear from available information)
Common side effects
Key clinical trials
- Galactol® Enzyme Supplement for Post-Prandial Abdominal Bloating in Irritable Bowel Syndrome (NA)
- AN-PEP on Gluten Exposure in Celiacs (PHASE4)
- Effect of AN-PEP Enzyme on Gluten Digestion in Gluten Sensitive Individuals (NA)
- Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients (PHASE2)
- Safety and Efficacy of ALV003 for the Treatment of Celiac Disease (PHASE2)
- Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prolyl Endopeptidase CI brief — competitive landscape report
- Prolyl Endopeptidase updates RSS · CI watch RSS
- Dr. C. Bonorino Udaondo Gastroenterology Hospital portfolio CI
Frequently asked questions about Prolyl Endopeptidase
What is Prolyl Endopeptidase?
How does Prolyl Endopeptidase work?
What is Prolyl Endopeptidase used for?
Who makes Prolyl Endopeptidase?
Is Prolyl Endopeptidase also known as anything else?
What drug class is Prolyl Endopeptidase in?
What development phase is Prolyl Endopeptidase in?
What does Prolyl Endopeptidase target?
Related
- Drug class: All Serine protease / Enzyme drugs
- Target: All drugs targeting Prolyl endopeptidase (PEP)
- Manufacturer: Dr. C. Bonorino Udaondo Gastroenterology Hospital — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastrointestinal disorders (specific indication unclear from available information)
- Also known as: GliadinX
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing